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Gregory L. Moneta, MD, Abstracts Section EditorThe ulcerated leg severity assessment score for prediction of venous leg
ulcer healing
Kulkarni SR, Gohel MS, Minor WJ, et al. Br J Surgery 2007;94:189-93.
Conclusion: The Ulcerated Leg Severity Assessment (ULSA) score
identifies patients with venous ulcers unlikely to respond to conventional
treatment.
Summary:Most, but not all, venous ulcers will heal with compression
therapy. The authors sought to develop an assessment score to potentially
identify patients whose ulcers would not heal with conventional compres-
sion therapy and, therefore, should perhaps be offered alternative therapy for
ulcer healing early in their course. Baseline factors affecting venous ulcer
healing were assessed in patients with venous ulcers seen between March
1999 and August 2001. All patients were initially treated with multilayer
compression therapy. Variables related to 24-week healing were identified,
and a Cox regression model was developed to identify risk factors that
predicted ulcer healing. From this model, a scoring system was developed
and subsequently prospectively validated between February 2004 andMarch
2005.
The baseline study included 229 patients with venous ulcers. Patient
age, ulcer chronicity, and venous refill time (VRT) of 20 seconds were
identified as risk factors for nonhealing. The authors used these risk factors
and hazard ratios from the Cox analysis and derived the following formula:
Ulcerated Leg Severity Assessment (ULSA) score  age  chronicity – 50
(when VRT is 20 seconds). Patients with an ULSA score 50 had higher
24-week ulcer-healing rates than those with scores50. This was in both the
baseline study (P  .001) and the follow-up prospective validation study
performed in 86 patients (P  .007).
Comment: Optimal therapy for venous ulceration continues to be
debated. The authors suggest that an elevated ULSA score may indicate
patients who early in the course of treatment may benefit from therapies
other than compression therapy. Their data, however, shows no benefit with
use of these “alternative” therapies. It only identifies individuals who will not
do well with compression therapy. It certainly cannot be assumed patients
who do not do well with compression therapy will be benefited by alternative
therapies. Alternative therapies may also not work well in patients with
elevated ULSA scores.
Homocystine-lowering therapy and risks for venous thromboembo-
lism: A randomized trial
Ray JG, Kearon C, Yi Q. The Heart Outcomes Prevention Evaluation 2
(HOPE-2) Investigators. Ann Intern Med 2007;146:761-7.
Conclusion: The risk of symptomatic venous thromboembolism
(VTE) is not decreased by lowering homocystine levels with folic acid and
vitamins B6 and B12.
Summary: Elevated homocystine levels are a risk factor for VTE. It is,
however, unknown whether decreasing homocystine levels with vitamin
therapy will lower the risk of VTE. The authors sought to determine whether
lowering homocystine levels will lower the risk of symptomatic VTE. This
was a secondary analysis of data obtained as part of the Heart Outcomes
Prevention Evaluation 2 (HOPE-2) trial. Data were derived from 145
centers in 13 countries. Included in the study were 5522 persons aged 55 or
older who had diabetes or known cardiovascular disease with at least one risk
factor for vascular disease. Patients were randomized to receive vitamin
therapy consisting of 2.5 mg of folic acid, 1 mg of vitamin B12, and 50 mg
of vitamin B6, or to receive placebo. Medications were administered for 5
years. End points included symptomatic deep venous thrombosis or pulmo-
nary embolism.
In patients treated with vitamin therapy, the mean homocystine level
decreased 2.2 mol/L. In the placebo group, mean homocystine levels
increased 0.80 mol/L. There were 88 instances VTE with a mean fol-
low-up of 5 years. VTE rate was the same in the vitamin therapy group and
the placebo group (0.35/100 person-years; hazard ratio, 1.01; 95% confi-
dence interval [CI], 0.66 to 1.53). The risk for deep venous thrombosis was
not reduced by vitamin therapy (hazard ratio, 1.04; 95% CI, 0.63 to 1.72),
nor was the risk of pulmonary embolism (hazard ratio, 1.14; 95%CI, 0.57 to
2.28) or unprovoked VTE (hazard ratio, 1.21; 95% CI, 0.66 to 2.23).
Comment: The HOPE-2 trial evaluated the effect of homocystine-
lowering therapy on major arterial vascular disease. This article represents a
secondary analysis of the HOPE 2 trial. The trial did not include patients
specifically at high risk for VTE. Elevated homocystine is a relatively minor
risk factor for VTE, and therefore, it is not surprising that the minor decrease
in homocystine levels associated with vitamin therapy in the HOPE 2
participants did not result in a detectable rate of decrease of VTE. The data
1080cannot be applied to patients at high risk for VTE or those with markedly
elevated levels of homocystine. Nevertheless, this is another of a number of
studies that indicate that although elevated homocystine may be a risk factor
or marker for venous or arterial disease, vitamin therapy to lower the
homocystine levels does not appear to clinically affect vascular events.
Dental and periodontal status and risk for progression of carotid
atherosclerosis: The Inflammation and Carotid Artery Risk for Athero-
sclerosis Study dental substudy
Schillinger T, Kluger W, Exner M, et al. Stroke 2006;37:2271-6.
Conclusion:Oral hygiene and tooth loss are associated with increased
levels of carotid stenosis and predict future progression of carotid artery
atherosclerosis.
Summary: There may be a link between periodontal and dental disease
and atherosclerosis. It is suggested that chronic inflammation triggered by
periodontitis plays a role in the etiology of atherosclerosis. In this study, the
authors studied a subset of patients from the Inflammation and Carotid
Artery Risk for Atherosclerosis study. This is a prospective study involving
serial ultrasound assessments of patients likely to have clinically relevant
atherosclerosis of the carotid artery. For the current study, 411 patients were
randomly selected from the 1268 participants in the Inflammation and
Carotid Artery Risk for Atherosclerosis study. Patients were evaluated for
dental and periodontal status and oral hygiene at study entrance using three
World Health Organization validated indices: DMFT (decayed, missing,
filled teeth), SLI (Silness-Lowe index), and CPITN (community periodon-
tal index for treatment needs), respectively. Carotid duplex ultrasound was
used tomeasure carotid stenosis at baseline and after a median of 7.5months
(range, 6 to 9 months).
DMFT (P  .01), SLI (P  .048), CPITN (P  .007), and edentu-
lousness (P  .007) all were associated with baseline levels of carotid
stenosis. During this study period, progression of carotid stenosis was noted
in 48 of 411 patients (11.7%). Adjusted odds ratios were 1.11 (95%
confidence interval [CI], 1.01 to 1.22, P .032) for DMFT, 1.77 (95% CI,
1.09 to 2.79) for SLI, and 1.51 (95% CI, 0.89 to 2.45, P  0.16) for
CPITN. DMFT and SLI predicted disease progression independent of
cardiovascular risk factors and baseline degree of stenosis. Edentulous pa-
tients also had a higher risk for disease progression compared with patients
with teeth (adjusted odds ratio, 2.10; 95% CI, 106 to 4.16; P  .033).
Comment: The role of dental and periodontal disease in atherosclero-
sis is controversial. There are many possible explanations for an observed
association between dental disease and atherosclerosis, and unmeasured
cofounders like socioeconomics status may modify observed associations. It
may be that dental disease merely serves as an added inflammatory compo-
nent to an already inflammatory vascular disease or that transient bacteriemia
associated with poor dental hygiene affects the development of atheroscle-
rotic plaques. Speculation with regard to the role of dental disease and the
etiology of atherosclerosis will continue. There are so many potential known
and unknown confounding variables that it is very unlikely this question will
ever be settled to anyone’s satisfaction.
Smoking, hypertension, alcohol consumption and risk of abdominal
aortic aneurysm in men
Wong DR, Willett WC, Rimm EB. Am J Epidemiol 2007;165:838-45.
Conclusion: Alcohol consumption correlates with the diagnosis of
abdominal aortic aneurysm (AAA).
Summary:Moderate alcohol consumption appears to have a protective
effect for ischemic heart disease. Little known, however, about the effects of
alcohol consumption and AAA. The authors analyzed prospective, biannu-
ally updated data from the Health Professionals Follow-up Study (HPFS).
This is a prospective cohort of 51,529 United States men who were aged 40
to 75 years at the inception of the study in 1986. The authors excluded from
this analysis individuals without complete dietary alcohol information in the
database, those with a history of ischemic cardiac disease, and those with
history of stroke or transient ischemic attack. Also excluded were nondrink-
ers who had never used alcohol or who had stopped using alcohol during the
previous 10 years. This left 39,352men for analysis. The authors determined
the association between alcohol consumption in grams per day and the
incident diagnosis of AAA. This was assessed at baseline and updated every 4
years. Data were controlled for previously reported cardiovascular risk
factors.There were 576,374 person-years of follow-up and 376 newly diag-
nosed AAAs. Adjusting for other risk factors for AAA (smoking, hyperten-
